Daily oral administration of probiotics engineered to constantly secrete short-chain fatty acids effectively prevents myocardial injury from subsequent ischaemic heart disease
Cardiovascular Research · 25.11.2024 · 120 (14) · 1737-1751
DOI: 10.1093/cvr/cvae128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 08.06.2024. Verfasst von Quynh Hoa Pham und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, College of Veterinary Medicine and Life Science, City University of Hong Kong, 83 Tat Chee Avenue, Hong Kong Speci…. Hauptthemen laut MEDLINE: Probiotics, Disease Models, Animal, Mice, Inbred C57BL, Myocardial Reperfusion Injury. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Grants Council, University Grants Committee, Health and Medical Research Fund.
Abstract (Originalsprache)
Aims
Given the extremely limited regeneration potential of the heart, one of the most effective strategies to reduce the prevalence and mortality of coronary artery disease is prevention. Short-chain fatty acids (SCFAs), which are by-products of beneficial probiotics, have been reported to possess cardioprotective effects. Despite their beneficial roles, delivering SCFAs and maintaining their effective concentration in plasma present major challenges. Therefore, in the present study, we aimed to devise a strategy to prevent coronary heart disease effectively by using engineered probiotics to continuously release SCFAs in vivo. Methods and results We engineered a novel probiotic cocktail, namely EcN_TL, from the commercially available Escherichia coli Nissle 1917 (EcN) strain to continuously secrete SCFAs by introducing the propionate and butyrate biosynthetic pathways. Oral administration of EcN_TL enhanced and maintained an effective concentration of SCFAs in the plasma. As a preventative strategy, we observed that daily intake of EcN_TL for 14 days prior to ischaemia–reperfusion injury significantly reduced myocardial injury and improved cardiac performance compared with EcN administration. We uncovered that EcN_TL’s protective mechanisms included reducing neutrophil infiltration into the infarct site and promoting the polarization of wound healing macrophages. We further revealed that SCFAs at plasma concentration protected cardiomyocytes from inflammation by suppressing the NF-κB activation pathway.
Conclusion
These data provide strong evidence to support the use of SCFA-secreting probiotics to prevent coronary heart disease. Since SCFAs also play a key role in other metabolic diseases, EcN_TL can potentially be used to treat a variety of other diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, College of Veterinary Medicine and Life Science, City University of Hong Kong, 83 Tat Chee Avenue, Hong Kong Special Administrative Region.
- Tung Biomedical Sciences Centre, City University of Hong Kong, 83 Tat Chee Avenue, Hong Kong Special Administrative Region.
- Department of Biomedicine and Health Sciences, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 137701, Korea.
- Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 137701, Korea.
ORCID-Profile: Kiwon Ban
Förderung
- Research Grants Council
- University Grants Committee
- Health and Medical Research Fund
- Food and Health Bureau, Hong Kong
- Tung Biomedical Sciences Centre
- City University of Hong Kong
- Croucher Foundation
- National Research Foundation of Korea
Zitieren
APA
Pham, Q. H., Bui, T. V. A., Sim, W. S., Lim, K. H., Law, C. O. K., Tan, W., Kim, R. Y., Chow, K. T., Park, H. J., Ban, K., & Lau, T. C. K. (2024). Daily oral administration of probiotics engineered to constantly secrete short-chain fatty acids effectively prevents myocardial injury from subsequent ischaemic heart disease. Cardiovascular Research, 120(14), 1737-1751. https://doi.org/10.1093/cvr/cvae128
Vancouver
Pham QH, Bui TVA, Sim WS, Lim KH, Law COK, Tan W, et al. Daily oral administration of probiotics engineered to constantly secrete short-chain fatty acids effectively prevents myocardial injury from subsequent ischaemic heart disease. Cardiovascular Research. 2024;120(14):1737-1751. doi:10.1093/cvr/cvae128
BibTeX
@article{Pham2024,
author = {Pham, Quynh Hoa and Bui, Thi Van Anh and Sim, Woo-Sup and Lim, King Hoo and Law, Carmen Oi Kwan and Tan, Wanyu and Kim, Ri Youn and Chow, Kwan Ting and Park, Hun-Jun and Ban, Kiwon and Lau, Terrence Chi Kong},
title = {Daily oral administration of probiotics engineered to constantly secrete short-chain fatty acids effectively prevents myocardial injury from subsequent ischaemic heart disease},
journal = {Cardiovascular Research},
year = {2024},
volume = {120},
number = {14},
pages = {1737--1751},
doi = {10.1093/cvr/cvae128}
}
EUVIMED